Drug and pharmaceutical giant Johnson & Johnson has agreed to pay $1.75 billion in cash to acquire Alios BioPharma, a private biotechnology company developing a medicine to combat a serious childhood respiratory infection for which there is no current treatment, the companies announced Tuesday.
South San Francisco-based Alios currently is in Phase II of development of an oral antiviral medication called AL-8176 for RSV, or respiratory syncytial virus, a disease that generally afflicts infants and children under the age of 5. The company also is developing a portfolio of potential treatments for other viral respiratory infections, including influenza, rhinovirus and coronavirus, according to Alios.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
